Can molecular patterns help to classify overlapping entities in myeloid neoplasms?

被引:1
|
作者
Hoermann, Gregor [1 ]
Khoury, Joseph D. [2 ]
机构
[1] MLL Munich Leukemia Lab, Munich, Germany
[2] Univ Nebraska Med Ctr, Nebraska Med Ctr 985900, Dept Pathol Microbiol & Immunol, Omaha, NE 68198 USA
关键词
chronic myelomonocytic leukaemia; disease classification; genetics; molecular patterns; myelodysplastic neoplasms; myeloid neoplasms; myeloproliferative neoplasms; systemic mastocytosis; EARLY PRIMARY MYELOFIBROSIS; TYROSINE KINASE JAK2; CLONAL HEMATOPOIESIS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; RING SIDEROBLASTS; MYELODYSPLASTIC SYNDROMES; INTEROBSERVER VARIANCE; REFRACTORY-ANEMIA; SETBP1; MUTATIONS;
D O I
10.1111/his.15339
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myeloid neoplasms include myeloproliferative and myelodysplastic neoplasms and acute myeloid leukaemia. Historically, these diseases have been diagnosed based on clinicopathological features with sometimes arbitrary thresholds that have persisted even as molecular features were gradually incorporated into their classification. As such, although current diagnostic approaches can classify the majority of myeloid neoplasms accurately using a combination of molecular and clinicopathological features, some areas of overlap persist and occasionally pose diagnostic challenges. These include overlap across BCR::ABL1-negative myeloproliferative neoplasms; between clonal cytopenia of undetermined significance and myelodysplastic neoplasms; myelodysplastic/myeloproliferative neoplasms; and, detection of KIT mutations in myeloid neoplasms other than mastocytosis, raising the prospect of systemic mastocytosis. Molecular testing has become state of the art in the diagnostic work-up of myeloid neoplasms, and molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. For future development, molecular testing will likely include whole genome and transcriptome sequencing, and primarily molecular classifications of myeloid neoplasms have already been suggested. As such, genetically defined groups should still constitute the basis for our understanding of disease development from early onset to progression, while clinicopathological features could then be used to describe the stage of the disease rather than the specific type of myeloid neoplasm. Molecular testing has become state of the art in the diagnostic work-up of myeloid neoplasms and molecular features have been incorporated into their classification, together with clinicopathological features. Molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. image
引用
收藏
页码:146 / 157
页数:12
相关论文
共 41 条
  • [1] Molecular Pathology of Myeloid Neoplasms Molecular Pattern Recognition
    Sadigh, Sam
    Kim, Annette S.
    CLINICS IN LABORATORY MEDICINE, 2024, 44 (02) : 339 - 353
  • [2] Molecular findings in myeloid neoplasms
    Tran, Tho B. B.
    Siddon, Alexa J. J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 (04) : 442 - 448
  • [3] Overlapping Stromal Alterations in Myeloid and Lymphoid Neoplasms
    Bogun, Lucienne
    Koch, Annemarie
    Scherer, Bo
    Germing, Ulrich
    Fenk, Roland
    Maus, Uwe
    Bormann, Felix
    Koehrer, Karl
    Petzsch, Patrick
    Wachtmeister, Thorsten
    Kobbe, Guido
    Dietrich, Sascha
    Haas, Rainer
    Schroeder, Thomas
    Geyh, Stefanie
    Jaeger, Paul
    CANCERS, 2024, 16 (11)
  • [4] Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms A Report of the Association for Molecular Pathology
    McClure, Rebecca F.
    Ewalt, Mark D.
    Crow, Jennifer
    Temple-Smolkin, Robyn L.
    Pullambhatla, Mrudula
    Sargent, Rachel
    Kim, Annette S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (06) : 717 - 737
  • [5] Updates in molecular genetics of therapy-related myeloid neoplasms
    Cantu, Miguel Dario
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2023, 40 (03) : 182 - 186
  • [6] Molecular Pathogenesis in Myeloid Neoplasms with Germline Predisposition
    Gao, Juehua
    Chen, Yihua
    Sukhanova, Madina
    LIFE-BASEL, 2022, 12 (01):
  • [7] Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia
    Malcovati, Luca
    Papaemmanuil, Elli
    Ambaglio, Ilaria
    Elena, Chiara
    Galli, Anna
    Della Porta, Matteo G.
    Travaglino, Erica
    Pietra, Daniela
    Pascutto, Cristiana
    Ubezio, Marta
    Bono, Elisa
    Da Via, Matteo C.
    Brisci, Angela
    Bruno, Francesca
    Cremonesi, Laura
    Ferrari, Maurizio
    Boveri, Emanuela
    Invernizzi, Rosangela
    Campbell, Peter J.
    Cazzola, Mario
    BLOOD, 2014, 124 (09) : 1513 - 1521
  • [8] Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers
    Khalife-Hachem, Sabine
    Saleh, Khalil
    Pasquier, Florence
    Willekens, Christophe
    Tarabay, Anthony
    Antoun, Leony
    Grinda, Thomas
    Castilla-Llorente, Cristina
    Duchmann, Matthieu
    Quivoron, Cyril
    Auger, Nathalie
    Saada, Veronique
    Delaloge, Suzette
    Leary, Alexandra
    Renneville, Aline
    Antony-Debre, Ileana
    Rosselli, Filippo
    De Botton, Stephane
    Salviat, Flore
    Marzac, Christophe
    Micol, Jean-Baptiste
    HEMASPHERE, 2021, 5 (09):
  • [9] Molecular studies of lung neuroendocrine neoplasms uncover new concepts and entities
    Fernandez-Cuesta, Lynnette
    Foll, Matthieu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S430 - S434
  • [10] Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
    Negoro, E.
    Radivoyevitch, T.
    Polprasert, C.
    Adema, V.
    Hosono, N.
    Makishima, H.
    Przychodzen, B.
    Hirsch, C.
    Clemente, M. J.
    Nazha, A.
    Santini, V.
    McGraw, K. L.
    List, A. F.
    Sole, F.
    Sekeres, M. A.
    Maciejewski, J. P.
    LEUKEMIA, 2016, 30 (12) : 2405 - 2409